Emcure Pharmaceuticals (NSE:EMCURE) Operating Margin %: 15.35% (As of Mar. 2026) — Near Median


NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
41 GF Score
Price ₹1,880.20
! 5 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals Operating Margin %?

Emcure Pharmaceuticals NSE:EMCURE +2.18% 41 Operating Margin % is 15.35% as of Mar. 2026, which is 0% below its 10-year median of 15.39. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Emcure Pharmaceuticals ranks better than 70.68% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Emcure Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was ₹3,792 Mil. Emcure Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was ₹24,697 Mil. Therefore, Emcure Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 was 15.35%.

Warning Sign:

Emcure Pharmaceuticals Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -6.6%.

The historical rank and industry rank for Emcure Pharmaceuticals's Operating Margin % or its related term are showing as below:

NSE:EMCURE' s Operating Margin % Range Over the Past 10 Years
Min: 13.74   Med: 15.39   Max: 19.43
Current: 14.92


NSE:EMCURE's Operating Margin % is ranked better than
70.68% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs NSE:EMCURE: 14.92

Emcure Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was -6.60% per year.

Emcure Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was ₹3,792 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹13,736 Mil.


Emcure Pharmaceuticals  (NSE:EMCURE) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Emcure Pharmaceuticals Operating Margin % Related Terms


Emcure Pharmaceuticals Operating Margin % Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Operating Margin % Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Margin %
Get a 7-Day Free Trial 18.86 15.86 13.94 13.74 14.92

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.85 14.49 14.74 15.04 15.35

NSE:EMCURE vs ZTS: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emcure Pharmaceuticals Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Emcure Pharmaceuticals's Operating Margin % falls into.


NSE:EMCURE
41GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emcure Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Emcure Pharmaceuticals's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (A: Mar. 2026 ) / Revenue (A: Mar. 2026 )
=13735.61 / 92035.4
=14.92 %

Emcure Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=3792.07 / 24697.03
=15.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 15.35% mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a Operating Margin % of 15.35% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Emcure Pharmaceuticals and its competitors. This is near median its historical median of 15.39. Over the past decade, Emcure Pharmaceuticals' Operating Margin % has ranged from 13.74 to 19.43. According to the industry distribution chart, Emcure Pharmaceuticals ranks #280 out of 955 companies in the Drug Manufacturers industry, placing it in the top 29.3%.
Is Emcure Pharmaceuticals' Operating Margin % too high?
Emcure Pharmaceuticals' current Operating Margin % of 15.35% is near median its 10-year median of 15.39. Over the past 10 years, this metric has ranged from a low of 13.74 to a high of 19.43. The Drug Manufacturers industry median Operating Margin % is 7.45. Emcure Pharmaceuticals' value of 15.35% is 106% above this industry median. Based on the distribution chart, Emcure Pharmaceuticals ranks #280 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #280 out of 955 companies for Operating Margin %. This puts Emcure Pharmaceuticals in the upper half of its industry. The industry median Operating Margin % is 7.45. Emcure Pharmaceuticals' value of 15.35% is 106% above this benchmark. Historically, Emcure Pharmaceuticals' own Operating Margin % has ranged from 13.74 to 19.43 over the past decade. While the company's 10-year median is 15.39 vs. the industry median of 7.45, Emcure Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emcure Pharmaceuticals's current Operating Margin % of 15.35% is 106% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Emcure Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emcure Pharmaceuticals's current Operating Margin % is 15.35%, which is near median its own 10-year median of 15.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Operating Margin % of 15.35%. The current Operating Margin % is 15.35%, which is near median its 10-year median of 15.39 and 106% above the Drug Manufacturers industry median of 7.45. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Operating Margin % is 15.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score

Get the complete analysis for NSE:EMCURE

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,880.20
Price